Favorable Prognosis in Patients With Multiple Myeloma and Lenalidomide-Induced Skin Rash: A Multicenter Retrospective...

Area of Science:

• Oncology
• Clinical Pharmacology

Background:

• Lenalidomide is a key treatment for multiple myeloma (MM).
• Skin rash is a frequent adverse event associated with lenalidomide therapy.

Purpose of the Study:

• To investigate the prognostic significance of skin rash development during lenalidomide treatment in relapsed/refractory MM patients.
• To determine if skin rash is an independent predictor of disease progression and survival.

Main Methods:

• Retrospective analysis of 245 relapsed/refractory MM patients treated with lenalidomide across 10 hospitals (July 2009 - December 2015).
• Evaluation of the association between skin rash occurrence and progression-free survival (PFS) and overall survival (OS).
• Multivariate regression analysis to identify prognostic factors, including skin rash.

Main Results:

• 70 out of 245 patients developed skin rashes.
• Patients with skin rashes had a median PFS of 22.4 months vs. 10.5 months for those without (p=0.003).
• Median OS was 42.6 months for patients with skin rash compared to 24.6 months for those without (p=0.013).
• Skin rash was identified as an independent prognostic factor for PFS (p=0.009).

Conclusions:

• Lenalidomide-associated skin rash may serve as a positive prognostic marker in multiple myeloma.
• Patients developing skin rash during lenalidomide treatment exhibit significantly improved clinical outcomes.